This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Liraglutide

Dosage Form; Route: Solution; subcutaneous

Strength: 18 mg/3 mL (6 mg/mL)

Recommended Study: Request for waiver of in vivo bioequivalence study requirements

I. Waiver:
To qualify for a waiver of the in vivo bioequivalence (BE) study requirement on the basis that BE is self-evident under 21 CFR 320.22(b), a generic liraglutide subcutaneous solution for injection product must be qualitatively (Q1)\(^1\) and quantitatively (Q2)\(^2\) the same as the Reference Listed Drug (RLD).

An applicant may seek approval of a drug product that differs from the RLD in preservative, buffer, or antioxidant provided that the applicant identifies and characterizes the differences and provides information demonstrating that the differences do not affect the safety or efficacy of the proposed drug product.\(^3\)

Please refer to FDA’s guidance for industry, *ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin*, for additional recommendations on when an application for generic liraglutide injection solution product should be submitted as an abbreviated new drug application (ANDA).

\(^1\) Q1 (Qualitative sameness) means that the test product uses the same inactive ingredient(s) as the reference list drug product.

\(^2\) Q2 (Quantitative sameness) means that concentrations of the inactive ingredient(s) used in the test product are within ± 5% of those used in the reference listed drug product.

\(^3\) 21 CFR 314.94(a)(9)(iii).